<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="438">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514174</url>
  </required_header>
  <id_info>
    <org_study_id>1200.209</org_study_id>
    <nct_id>NCT02514174</nct_id>
  </id_info>
  <brief_title>Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older</brief_title>
  <official_title>A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuos treatment until progression or occurence of intolerable Adverse Event (AE) or end
      of trial. The end of trial is one year after the last patient has entered the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Occurrence of AEs leading to dose reduction of afatinib</measure>
    <time_frame>One year after LPE</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of CTCAE grade 3 or higher diarrhoea</measure>
    <time_frame>One year after LPE</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of CTCAE grade 3 or higher rash/acne+ (+ represents grouped term)</measure>
    <time_frame>One year after LPE</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of CTCAE grade 3 or higher stomatitis+ (+ represents grouped term)</measure>
    <time_frame>One year after LPE</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of CTCAE grade 3 or higher paronychia+ (+ represents groupded term)</measure>
    <time_frame>One year after LPE</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first dose reduction of afatinib caused by AE's, defined as time from the date of the first admiinistration of afatinib to the first dose reduction of afatinib caused by AE's.</measure>
    <time_frame>One year after LPE</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>ErbB Receptors</condition>
  <arm_group>
    <arm_group_label>Afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>afatinib starting at 30 mg daily dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>afatinib starting at 30 mg daily dose</description>
    <arm_group_label>Afatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Pathologically or cytologically confirmed NSCLC

          2. Stage IV Cancer (includes cytologically proven pleural effusion or pericardial
             effusion) or recurrent disease. The staging is based on American Joint Commitee on
             Cancer (AJCC) Classification of Malignant Tumours (TNM) 7th edition (R12-4710)

          3. Evidence of common EGFR mutation (Del 19 and/or L858R)

          4. Age = 70 years

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (R01- 0787)

          6. No prior systemic therapy for metastatic or recurrent NSCLC.

        Further inclusion criteria apply.

        Exclusion criteria:

          1. Prior participation in an afatinib clinical study, even if not assigned to afatinib
             treatment

          2. Concurrent investigational therapy or investigational therapy within 4 weeks of start
             of afatinib therapy

          3. Radiotherapy within 4 weeks prior to start of study treatment, except as follows:

             i.) Palliative radiation to target organs other than chest may be allowed up to 2
             weeks prior to study treatment, or ii.) Single dose palliative treatment for
             symptomatic metastasis outside above allowance to be discussed with sponsor prior to
             enrolling.

          4. Major surgery within 4 weeks before starting study treatment or scheduled for surgery
             during the projected course of the study

          5. Systemic chemotherapy, biological therapy, immunotherapy or investigational agents
             within 5 half-life of the drug or within four weeks prior to the start of afatinib
             treatment (if the half-life of the drug is unknown).

          6. Men, capable of fathering a child, who are unwilling to use adequate contraception
             prior to study entry, for the duration of study participation, and for at least 28
             days after treatment has ended.

        Further Exclusion Criteria Apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1200.209.20029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.209.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 15, 2016</lastchanged_date>
  <firstreceived_date>July 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
